Comparative Pharmacology
Head-to-head clinical analysis: DIMENHYDRINATE versus PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMENHYDRINATE versus PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE.
DIMENHYDRINATE vs PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimenhydrinate is a histamine H1 antagonist with central anticholinergic activity. It acts by blocking H1 receptors in the brain's vomiting center and inhibiting vestibular stimulation. It also has anticholinergic effects by binding to muscarinic receptors, reducing motion sickness.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic through blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Phenylephrine is a direct-acting sympathomimetic amine that selectively stimulates α1-adrenergic receptors, causing vasoconstriction and nasal decongestion.
50-100 mg orally or intramuscularly every 4-6 hours as needed; maximum 400 mg per day. For motion sickness, 50-100 mg 30 minutes before travel.
Each 5 mL oral solution contains promethazine hydrochloride 6.25 mg and phenylephrine hydrochloride 5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL (8 teaspoonfuls) per 24 hours.
None Documented
None Documented
Clinical Note
moderateDimenhydrinate + Venlafaxine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine."
Clinical Note
moderateDimenhydrinate + Nefazodone
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone."
Clinical Note
moderateDimenhydrinate + Stiripentol
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is 5-10 hours in adults, longer in elderly or hepatic impairment (up to 15 hours).
Promethazine: Terminal elimination half-life is approximately 10-14 hours in adults, ranging 5-14 hours; prolonged in hepatic impairment. Phenylephrine: Terminal elimination half-life is approximately 2-3 hours; clinically active for a shorter duration due to rapid metabolism.
Primarily renal, with 60-80% of the dose excreted unchanged in urine; minor biliary/fecal elimination accounts for <10%.
Promethazine: Renal excretion of metabolites and unchanged drug accounts for approximately 70-80% of elimination, with about 20-30% excreted in feces via biliary elimination. Phenylephrine: Primarily renal excretion as sulfate conjugates and unchanged drug; about 80% of a dose is excreted in urine within 48 hours, with minor fecal elimination (<10%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic
Dimenhydrinate + Clomipramine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine."